AspenBio Pharma Changes Company Name to Venaxis, Inc.
Company Provides Update Following Special Meeting of Shareholders
CASTLE ROCK, Colo., Dec. 12, 2012
CASTLE ROCK, Colo., Dec.12, 2012 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), formerly AspenBio Pharma, an in vitro diagnostic company, today
announced it has changed its corporate name after receiving approval from its
shareholders at a Special Meeting of Shareholders held on December 11, 2012.
The Company's common stock will continue to trade on the Nasdaq Capital Market
under the symbol "APPY". As part of its rebranding process Venaxis has also
changed the name of the Company's blood-based appendicitis diagnostic test in
development to "APPY1".
Steve Lundy, President and CEO of Venaxis, stated, "These changes represent
another major step forward in our corporate rebranding process and we are
pleased that our shareholders overwhelmingly supported our recent efforts to
align our corporate identity with our core in vitro diagnostics business. Our
goal is to become a recognizable name in the human diagnostics space and we
feel that the timing of these branding changes is auspicious, as we draw
closer to commercializing APPY1 in Europe and initiating a pivotal clinical
study for purposes of gaining regulatory clearance in the United States."
Venaxis is revising and updating the Company web site and corporate materials,
including the logo, and plans to unveil its new corporate look and investor
website shortly after the first of the year.
During the Special Shareholder Meeting, the Company's shareholders approved
all motions, including the proposed increase in the number of shares available
under its equity plan.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its blood-based appendicitis test,
APPY1. The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. APPY1 is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging. For more information, visit
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and
Exchange Commission ("SEC"). All statements, other than statements of
historical fact, included in this press release that address activities,
events or developments that Venaxis believes or anticipates will or may occur
in the future are forward-looking statements. These statements are based on
certain assumptions made based on experience, expected future developments and
other factors Venaxis believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of Venaxis. Investors are cautioned that
any such statements are not guarantees of future performance. Actual results
or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including our ability
to successfully complete required product development and modifications in a
timely and cost effective manner, complete clinical trial activities for APPY1
required for FDA submission, obtain FDA clearance or approval, complete and
obtain CE Mark, cost effectively manufacture and generate revenues from APPY1,
execute agreements required to successfully advance the company's objectives,
retain the management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and enforce
intellectual property rights, and realize value of intangible assets.
Furthermore, Venaxis does not intend (and is not obligated) to update publicly
any forward-looking statements. The contents of this press release should be
considered in conjunction with the risk factors contained in Venaxis' recent
filings with the SEC, including its Form 10-Q for the period ended September
30, 2012, filed on November 7, 2012.
For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
SOURCE Venaxis, Inc.
Press spacebar to pause and continue. Press esc to stop.